Recruiting PHASE1 INTERVENTIONAL 2-arm NCT07025018

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations

Sponsor: Hutchmed

Conditions Gliomas Harboring IDH1 and/or IDH2 Mutations

Interventions HMPL-306

Updated 2 times since 2025 Last updated: Jul 31, 2025 Started: Jul 15, 2025 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07025018, this PHASE1 trial focuses on Gliomas Harboring IDH1 and/or IDH2 Mutations and remains actively recruiting participants. Sponsored by Hutchmed, it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hutchmed

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China